Journal of the American Academy of Dermatology
Volume 53, Issue 6 , Pages 973-978, December 2005

Lipomas treated with subcutaneous deoxycholate injections

  • Adam M. Rotunda, MD

      Affiliations

    • From the Division of Dermatology, University of California Los Angeles, David Geffen School of Medicine
    • Corresponding Author InformationReprint requests: Adam M. Rotunda, MD, Bennett Surgery Center, St. John's Medical Plaza, Suite 590, Santa Monica, CA 90404.
  • ,
  • Glynis Ablon, MD

      Affiliations

    • Department of Dermatology, West Los Angeles Veteran Administration Medical Center
  • ,
  • Michael S. Kolodney, MD, PhD

      Affiliations

    • Division of Dermatology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance

Accepted 30 July 2005. published online 17 October 2005.

Los Angeles and Torrance, California

Background

Lipomas are benign neoplasms of mature fat cells. Current treatments are invasive and carry the risk of scarring. Injections of phosphatidylcholine solubilized with deoxycholate, a bile salt, have been used to reduce unwanted accumulations of fat. Recent in vitro and ex vivo investigations indicate that deoxycholate alone causes adipocyte lysis.

Objective

We sought to report our experience treating lipomas using subcutaneous deoxycholate injections.

Methods

A total of 6 patients presenting with 12 lipomas were treated with intralesional injections of sodium deoxycholate (1.0%, 2.5%, and 5.0%) at intervals of 2 to 20 weeks. Tumor size, cutaneous reactions, and patients' subjective responses were recorded before and after treatment.

Results

All lipomas decreased in size (mean area reduction, 75%; range, 37%-100%) as determined by clinical measurement (with ultrasound confirmation in one lipoma) after an average of 2.2 treatments. Several lipomas fragmented or became softer in addition to decreasing in volume. Adverse effects, including transient burning, erythema, and local swelling, were associated with higher deoxycholate concentrations but resolved without intervention. There was no clear association between deoxycholate concentration and efficacy.

Conclusions

Our clinical experience supports our laboratory investigations demonstrating that deoxycholate, rather than phosphatidylcholine, is the active ingredient in subcutaneously injected formulas used to treat adipose tissue. This small series suggests that low concentration deoxycholate may be a relatively safe and effective treatment for small collections of fat. However, controlled clinical trials will be necessary to substantiate these observations.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding sources: None.Disclosure: Drs Rotunda and Kolodney are co-developers of a patent-pending process owned by the Los Angeles Biomedical Institute and University of California Los Angeles that describes the use of detergents for the reduction of fat. The authors had no commercial interests or financial support for their work.

PII: S0190-9622(05)02586-7

doi:10.1016/j.jaad.2005.07.068

Journal of the American Academy of Dermatology
Volume 53, Issue 6 , Pages 973-978, December 2005